CIA
HUMA icon

Concurrent Investment Advisors’s Humacyte HUMA Stock Holding History

Concurrent Investment Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.8K Buy
68,979
+5,000
+8% +$4.63K ﹤0.01% 2063
2026
Q1 		$38.8K Buy
63,979
+4,000
+7% +$4.16K ﹤0.01% 1885
2025
Q4 		$57.6K Buy
59,979
+364
+0.6% +$515 ﹤0.01% 1737
2025
Q3 		$104K Buy
59,615
+8,500
+17% +$16.7K ﹤0.01% 1423
2025
Q2 		$107K Buy
51,115
+7,615
+18% +$14.6K ﹤0.01% 1324
2025
Q1 		$74.2K Buy
43,500
+11,200
+35% +$42K ﹤0.01% 1189
2024
Q4 		$163K Buy
32,300
+18,500
+134% +$91.5K ﹤0.01% 1015
2024
Q3 		$75.1K Buy
+13,800
New +$91K ﹤0.01% 1010

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Concurrent Investment Advisors's HUMA Position: Q2 2026 in Review

Concurrent Investment Advisors increased its Humacyte (HUMA) stake by 7.8% in Q2 2026, buying an estimated $4.63K and bringing the position to 68,979 shares worth $53.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2063.

Concurrent Investment Advisors first reported a position in HUMA in Q3 2024 and has held it in 8 quarters since. The position peaked at $163K in Q4 2024. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Concurrent Investment Advisors held 68,979 shares of Humacyte worth $53.8K as of Q2 2026.
  • Concurrent Investment Advisors bought 5,000 Humacyte shares in Q2 2026, an estimated $4.63K.
  • Humacyte made up ﹤0.01% of Concurrent Investment Advisors's portfolio in Q2 2026, its #2063 holding.
  • Concurrent Investment Advisors first reported a position in Humacyte in Q3 2024 and has held it in 8 quarters since.
  • Concurrent Investment Advisors's Humacyte position peaked at $163K in Q4 2024.
  • 161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.